Claves Life Sciences

Claves Life Sciences is a microbiome-focused therapeutics company within the Aptorum Group that develops candidates aimed at modulating gut microbiota-derived metabolites. The business is positioned in gastroenterology and metabolic disease, with a platform intended to generate custom candidates that fine-tune gut metabolite levels for disease prevention or treatment. Its best-disclosed program is CLS-1, an orally administered non-absorbable macromolecule being developed preclinically for obesity. Public materials and patent filings indicate an emphasis on sequestering metabolites such as acetate using molecularly imprinted polymer-based approaches. Claves appears to operate primarily as a private, wholly owned subsidiary rather than as an independent public operating company.